Medicinal cannabis and hemp company ECS Botanics Holdings Ltd (ASX: ECS) has successfully completed its first shipment of dried cannabis flower to Lyphe Group, the largest distributor of medicinal cannabis in the UK.
ECS has received purchase orders from Lyphe for the UK market for dried cannabis flower totalling over $500,000. These will be delivered over the coming months as product becomes available from the current harvest. ECS is working closely with Lyphe and expecting further orders over CY2022.
Lyphe delivers a patient-focused medical cannabis ecosystem, and has emerged as the UK’s market leader in patient care, seeing over 60% of the medical cannabis patients in the country. Lyphe delivers a reliable and seamless supply of medical cannabis care and medicine. It has built a patient-access ecosystem across the UK that provides clinics, pharmacy and dispensing, import infrastructure, and vital educational services to patients, doctors and other health care professionals.
ECS expects that the UK and Europe will become a significant market for the Company during 2022 and 2023, as demand increases for its high quality and competitively priced GMP certified products. ECS is currently performing additional ICH stability testing, required for product registration in many EU markets, expected to be complete within the next 6 months.
This shipment is a significant milestone for ECS, as it is the first international export of our Australian grown dried cannabis flower. We expect our product to be well received by patients in the UK, and demand for our flower to grow significantly through the year,” Managing Director, Alex Keach, said.
